Rational design and evaluation of new lead compound structures for selective βARK1 inhibitors

Journal of Medicinal Chemistry

Volumn 45, Issue 11, 2002, Pages 2150-2159

  Iino, Minoru ^a   Furugori, Taketoshi ^a   Mori, Tomohiro ^a   Moriyama, Sachiko ^a   Fukuzawa, Akiko ^a   Shibano, Toshiro ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR KINASE 1 INHIBITOR; G PROTEIN COUPLED RECEPTOR; LEAD; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ADRENERGIC RECEPTOR BLOCKING; ANALYTIC METHOD; ARTICLE; BINDING SITE; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; MOLECULAR RECOGNITION; PHARMACOPHORE;

BETA-ADRENERGIC RECEPTOR KINASE; BINDING SITES; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DATABASES, FACTUAL; DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037161582     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010093a     Document Type: Article

References (58)

1. Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads
2. Discovery of a novel dopamine transporter inhibitor, 4-Hydroxy-l-methyl-4-(4-methylphenyl)-3-piperidyl 4-Methylphenyl ketone, as a potential cocaine antagonist through 3D-Database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies
3. D Structure-based strategies for drug design and discovery
4. Structure-based discovery of inhibitors of thymidylate synthase
5. Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design
6. Computational screening of combinatorial libraries
7. Molecular docking towards drug discovery
8. Computer-based screening of compound databases for the identification of novel leads
9. A virtual screening approach applied to the search for trypanothione reductase inhibitors
10. Lead discovery of inhibitors of the dihydrofolate reductase domain of plasmodium falciparum dihydrofolate reductase-thymidylate synthase
11. Virtual screening - An overview
12. Conformational searching in ISIS/3D databases
13. Conformational freedom in 3-D databases. 1. Techniques
14. FLOG: A system to select "quasi-flexible" ligands complementary to a receptor of known three-dimensional structure
15. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4
16. Regulation of transmembrane signaling by receptor phosphorylation
17. Protein kinases that phosphorylate activated G protein-coupled receptors
18. Inhibition of β-adrenergic receptor kinase prevents rapid homologous desensitization of β2-adrenergic receptors
19. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart
20. Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart
21. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor
22. Substrate recognition mechanism of human β-adrenargic receptor kinase 1 based on a three-dimensional model structure
23. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase
24. Two distinct pathways for cAMP-mediated down-regulation of the β2-adrenergic receptor. Phosphorylation of the receptor and regulation of its mRNA level
25. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase
26. ATP-site directed inhibitors of cyclin-dependent kinases
27. Structures of the tyrosine Ktinase Dtomain of fibroblast growth factor receptor in complex with inhibitors
28. Asp278 of human β-adrenergic receptor kinase 1 is essential for phosphorylation activity
29. Conformation of amino acid side-chains in proteins
30. Computed conformational states of the 20 naturally occurring amino acid residues and of the prototype residue α-aminobutyric acid
31. Hydrogen bonding in globular proteins
32. Stable calculation of coordinates from distance information
33. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations
34. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure
35. Scoring noncovalent protein-ligand interactions: A continuous differentiable function tuned to compute binding affinities
36. LUDI: Rule-based automatic design of new substituents for enzyme inhibitor leads
37. VALIDATE: A new method for the receptor-based prediction of binding affinities of novel ligands
38. SCORE: A new empirical method for estimating the binding afiinity of a protein-ligand complex
39. Application of a theory of enzyme specificity to protein synthesis
40. The role of active site flexibility in enzyme catalysis
41. The application of three approximate free energy calculations methods to structure based ligand design: Trypsin and its complex with inhibitors
42. Phosphotransferase and substarte binding mechanism of the camp-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 Å structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24)
43. Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of camp-dependent protein kinase complexed with the peptide inhibitor PKI(5-24) and adenosine
44. Modeling protein structures: Construction and their applications
45. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2
46. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine
47. The structure-based design of ATP-site directed protein kinase inhibitors
48. Iterative partial equalization of orbital electronegativity - A rapid access to atomic charges
49. Purification and functional characterization of β-adrenergic receptor kinase expressed in insect cells
50. Toward a rational design of peptide inhibitors of ribonucleotide reductase: Structure-function and modeling studies
51. A novel approach for the development of selective Cdk4 inhibitors: Library design based on locations of Cdk4 specific amino acid residues
52. 2.2-Angstrom refinded crystal-structure of the catalytic subunit of cAMP-dependent protein-kinase complexed with Mn ATP and a peptide inhibitor